of sixteen countries from the region according to different criteria: characteristics, quality (using Drummond's checklist), use of local data, addressed inputs limitation and results transferability. Results: Economic evaluations are used in CEE countries for informing decision making, while critically considering methodology, quality and study's reliability. Experts acknowledged limited generalizability of study results both between and within geographic regions. Meanwhile, despite these constraints, facing limited health technology assessment (HTA) capacity experts were still using foreign evidence. At the same time, the usefulness of studies published in CEE and former Soviet countries to inform their decision making is limited because of insufficient transparency in reporting, unaddressed uncertainty, limited insight on inputs and transferability of results. Although local costs, baseline risk and resource use data are required, experts accept evidence originating from health care settings outside CEE and former Soviet countries regarding relative effect and utilities values. ConClusions: HTA priority setting and transferability assessment of economic evidence are important issue in health care decision making in CEE and former Soviet countries, since HTA research capacity is limited and local evidence is scarce. For this purpose, quality, transparency, and transferability should be addressed explicitly in published economic evaluations originating from CEE and former Soviet countries. BACkgRound: The Department of Science and Technology (DECIT) at the Ministry of Health (MoH), since 2003, has financed studies to support demands from the MoH technical areas regarding the decision making process about health technologies. oBjeCtives: To analyze DECIT performance in financed Health Technology Assessment (HTA) studies to improve the capacity building of HTA in Brazil. Methods: A retrospective descriptive study based on the analysis of documents and official records built in a single database in Excel containing the studies promoted by DECIT from 2003 to November 27, 2013. The variables pre-classified and collected from Brazilian Network for Health Technology Assessment's database, SISREBRATS, were revised by two reviewers and conferred or supplemented with data from the Database of Health Research, Annual Reports Management by DECIT, and Final Reports and Cooperation Agreements by co-financier partners.
oBjeCtives: Since January 2011, pharmaceutical manufacturers are obliged to submit dossiers presenting benefits over comparative treatment when launching new products in the German pharmaceutical market. These dossiers are usually evaluated by the Institute for Quality and Efficiency in Health Care (IQWiG) . Based on the dossier, the IQWiG's evaluation and a subsequent hearing process, the Federal Joint Committee (G-BA) decides on additional therapeutic benefit related to mortality, morbidity, quality of life (QoL) and side effects. As QoL is among the more contested of these criteria and remains comparably unspecified, this qualitative study's aim was to analyze definitions and the role of QoL in early assessments of benefit (EAB) in Germany. Methods: As most of the documents are freely available on the G-BA's website, this study included all relevant documents of the first completed 66 assessments (11.2011-12.2013 ). We conducted a qualitative content analysis screening the dossiers, IQWiG evaluations, G-BA decisions and the protocols of the oral hearing for relevant links to QoL and synonyms. In a process of independent analysis and joint consensus building by two researchers, relevant text passages were extracted and reduced to key content on the term's usage. During analysis, a system of codes was developed accounting for a wide variety of recurring QoL-related definitions and references to its importance. Results: Even though key players did not necessarily share the same QoL-definition, the concept's relative importance was highlighted in numerous references. G-BA decisions criticize the lack of or the inadequate presentation of QoL data in the manufacturer's dossiers. G-BA and IQWiG apply a narrow understanding of QoL, while manufacturers failed to establish wider notions of QoL linking factors such as patient satisfaction to the concept. ConClusions: QoL in a particular sense is of pivotal importance in Germany's early assessment of benefit. The demand for reliable QoL data is growing.
PHP240 an uPDaTe On clinical anD ecOnOmic eviDence reQuiremenTs fOr aDvanceD-THeraPY meDicinal PrODucTs in eurOPe
Anastasaki E. 1 , Walker A. 2 , Bradshaw S. 1 1 Market Access Solutions LLC, London, UK, 2 University of Glasgow, Glasgow, UK oBjeCtives: Advanced-therapy medicinal products (ATMPs), such as gene therapy, cell therapy and tissue engineering are a new class of medicines in the EU. ATMPs offer prospects in prevention and treatment of fatal and/or chronic debilitating diseases where no effective treatments exist. However, with complicated mechanisms of actions and benefits often being anticipated in the longer term, it is challenging to demonstrate hard clinical evidence and create robust cost-effectiveness models that Payers have come to expect at the launch of pharmaceuticals. Thus, manufacturers face difficulties when negotiating the price for ATMPs and may not be able to realize their full potential. This paper aims to use case studies of ATMPs launched in EU5 to outline access pathways and review the clinical and economic evidence requirements. Methods: Secondary research identified ATMP approvals since 2008 and a framework was created to develop hypotheses on clinical and economic evidence requirements, considering alternative routes to market. Hypotheses were then validated during in-depth interviews with key stakeholders across EU5. Results: Payers are yet to be convinced about the full benefit of ATMPs and are reluctant to pay premium prices if they are not sure about long-term efficacy and safety. Additionally, in their cost-benefit analyses, Payers tend to consider only the direct costs associated with a condition, ignoring broader societal benefits and savings in the long run. Therefore, price negotiations are sometimes lengthy. Risk sharing and novel payment-by-result schemes are often agreed to mitigate risks. ConClusions: Payers are not yet familiar with the potential value of ATMPs, and, in most cases specific evaluation criteria don't exist. Manufacturers need to invest in educating Payers on the huge differences between ATMPs and traditional therapies, particularly to show that manufacturing costs are substantial, and work together to identify relevant measures for clinical and economic evaluations of this new therapy class.
PHP241 rOmanian Quick-HTa DevelOPmenT in 2013
Radu C. P. , Cernea R. Roche Romania, Bucharest, Romania oBjeCtives: The Objectives are to present the characteristics of the quick-HTA started in June 2013 and to show the Results of the first quick-HTA process in Romania. Methods: The health care context and the Romanian legislation covering HTA were studied by considering: the reasons behind HTA introduction, the key stakeholders and the HTA process. A critical appraisal was done covering public HTA reports and the decisions taken by the Ministry of Health (MofH). Results: The introduction of quick-HTA began mid-June 2013 when MofH released the legislation and the HTA Unit started receiving dossiers for new drugs/indications. The HTA model was based on a "score-card" system with 6 criteria: HAS (France) opinion, NICE/SMC/AWMSG (UK) opinion, the number of EU countries with reimbursement, relative efficacy, relative safety and relative patient-reported-outcomes (PRO), but no role of budget impact. From June to December 2013, 167 HTA dossiers were evaluated by the HTA Unit with an acceptance rate of about 80%. Most of the drugs accepted for reimbursement were oncological (23%); other main therapeutic areas were diabetes with 16 drugs/indications receiving positive evaluations, rheumatology (14), oncohaematology (8) and neurology (7). The HTA included also biosimilars, all 4 of them receiving positive decisions. Unfortunately, early 2014, the new Government abrogated this HTA legislation and the already-published HTA reports, claiming that the process didn't mentioned the criteria for de-listing reimbursed drugs nor the budget impact, within HTA reports. Moreover, the HTA process was moved into the responsibility of the National Agency for Drugs. ConClusions: The implementation of the quick-HTA in Romania took a good start, using a mixture of information, from benefits and costeffectiveness in other countries, to relative effectiveness, safety and PRO. However, the lack of consideration for the local context and the political disagreements led to a temporary suspension of this quick-HTA process in Romania. Results: A total of 92 available CONITEC reports for 2012 (n= 38, 33 for medicines) and 2013 (n= 54, 42 for medicines) were analyzed. 45% of reports on medicines recommended incorporation into the SUS. Most of the positive recommendations were clearly related to public health priorities as identified by the government, translating a strong commitment for improved access to medicines within the SUS i.e. anti-cancer drugs. Overall, the creation of the CONITEC represents a substantial step toward the institutionalization of HTA, with more transparency and accountability in decision-making processes, considering ethical, organizational, social, and legal aspects. ConClusions: Whereas lowest in Russia, India and South Africa, and at a transitional stage in China, Brazil has a comparable degree of institutionalization of HTA as countries with a long-lasting HTA experience. A best-practice assessment in the area of HTA within the BRICS has still to be elaborated. Transferability of lessons learned might be a strong tool for improving HTA development within the BRICS.
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HTa in THe Brazilian HealTH care sYsTem anD POTenTial lessOns learneD fOr OTHer Brics sTaTes
PHP243 is g-Ba sTraTegicallY DiscOunTing THe BenefiT assessmenT Of relaTivelY HigH cOsT Drugs?
Jaksa A. , Daniel K. , Bergemann R. , Ho Y. S. Context Matters, Inc., New York, NY, USA oBjeCtives: Gemeinsame Bundesausschuss (G-BA) states that it assesses additional benefit strictly on clinical grounds, but it also requires that manufacturers submit drug and comparator costs. This raises the possibility that G-BA's assessment might be influenced by price, possibly to provide leverage during subsequent price negotiations. This research tests the hypothesis that high cost drugs (relative to the comparator) are more likely to receive poor benefit assessments. Methods:
The following variables were collected from the Federal Gazette publication or the "Beschluss" document: additional benefit assessment, annual cost per patient of drug and comparator, and estimated target population. The Scottish Medicines Consortium (SMC) clinical rationale for the same drugs and indications were collected to control for clinical efficacy. After excluding orphan drugs, reviews using best supportive care comparators, and reviews without SMC reviews, 58 reviews remained for analysis. G-BA's additional benefit assessments were ranked from least benefit to most. The influence of drug cost relative to the comparator on the G-BA assessment was estimated via an ordered logit model. The model also included controls for the (log) size of the target population and clinical efficacy (SMC's clinical assessment). Results: An increase in the cost difference between the drug and the comparator is estimated to result in a modest, statistically significant increase in the odds of receiving an additional benefit assessment greater than a "no additional benefit" assessment. ConClusions: Our results are inconsistent with the alternative hypothesis that G-BA is strategically discounting its assessment of relatively high cost drugs. The positive estimated relationship is consistent with manufacturers' setting higher prices for more beneficial drugs (The data available provide no way to statistically account for this plausible source of endogeneity). Our results provide no support for rejecting the null hypothesis that G-BA assesses added benefit independently of drug cost. oBjeCtives: The aim of this study was to assess the development of HTA in Turkey. Methods: In this regard, organization structures of the Ministry of Health (MoH) and Social Security Institution (SSI) and presentations of first HTA meeting held in April 2014 have been analyzed. Results: There are three main HTA agencies in Turkey. One is under the payer institution called SSI. The HTA committee of SSI assesses all the new health technologies to define whether they will be reimbursed or not. In other words, this committee is the major decisive HTA committee. Other two HTA committees are under the MoH. One of these is under the General Directorate of Pharmaceuticals and Medical Devices. This committee assesses certain drugs which are specifically asked to be evaluated by the SSI, MoH or other Ministries. One of the projects completed by this committee is the evaluation of top 100 selling drugs according to the effect of price, regulation, market and qualitative characteristics of drugs. The second committee of the MoH is under the General Directorate of Health Research. This committee assesses more general issues like obesity, KOAH etc., instead of certain health technologies and publishes national reports. One of the reports published by this committee was the importance of obesity surgery in the treatment of obesity. In addition to all these three committees, HTA studies also being carried out by a MoH hospital called Ankara Numune Training and Research Hospital (ANHTA). They have been working on hospital based HTA. ConClusions: Despite valuable studies being conducted as stated above, HTA is still in its infancy in Turkey and compared to other EU countries like Germany, UK etc. there is not an autonomous HTA agency. There are more than one committee, working on different aspects of health technology assessment under the supervision of government.
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DevelOPmenT Of HTa in TurkeY
PHP245 Disease BurDen in Brazil anD HealTH TecHnOlOgY assessmenT: a reTrOsPecTive Of Ten Years Of suPPOrTing
Koury C. D. N. 1 , Elias F. T. S. 2 1 FIPE -Fundação de Ensino e Pesquisas Econômicas, Brasilia, Brazil, 2 Ministry of Health of Brazil, Brasilia, Brazil BACkgRound: Defining health technology assessment priorities has been a challenge for the Department of Science and Technology who adopted a prioritization criteria strategy (epidemiologic relevance, services/policy relevance, state of the art, operational feasibility and social demand) for demands from MoH technical areas. However, evaluation demands do not always correspond to health needs. oBjeCtives: To analyze the relationship between projects financed from 2003 to 2013 and disease burdens in Brazil. Methods: Systematization of the summaries from financed projects through searches in the information from www.saude.gov.br/ rebrats and http://pesquisasaude.saude.gov.br/bdgdecit/ and categorization according to the twenty sub-groups of diseases and injuries of disease burden (Dalys) research in Brazil (SHARMM ET al, 1998) . Results: 284 HTA projects financed between 2003 and 2013. Of these, 24% (68/284) apply to the twenty main causes of loss of life years by premature death or incapacitation (Dalys, 1998) . The first three largest are equal to 15% -diabetes, coronary ischemia, acute myocardial infarction, angina, cerebral infarction and stroke-corresponded to 13% of the (37/284) projects. ConClusions: The percentage found allows for the questioning of the prioritization starting point where the criteria are applied to subjects selected due to external influence and pressure from the market and not necessarily based on the needs impacting the population's health. Uniting the two dimensions while also taking into account the strategic innovations in order to prioritize and finance assessment will be important for health systems sustainability.
PHP246 firsT exPeriences WiTH THe neW TesTing examinaTiOn anD TreaTmenT: meTHODs in germanY: is THis a neW amnOg clOne?
Bonduelle D. 1 , Eheberg D. 2 , Plantoer S. 1 1 IMS HEALTH GmbH & Co. OHG, Munich, Germany, 2 IMS HEALTH, Munich, Germany oBjeCtives: In a new regulation the Federal Joint Committee (G-BA) can pass directives for testing examination and treatment methods with not yet sufficiently proven benefit, but which show potential as essential treatment alternatives ( §137e SGB V). The objective of the present study was to compare the requirements for a successful application with the existing AMNOG (Law on the Reorganization of the Pharmaceutical Market) HTA requirements in Germany. The applicants must submit valid data on the potential of the method in question, among other requirements. In one of the first applications in Germany, done by the authors, we see a lot of parallels with the HTA process for drugs but also a lot of uncertainties. Methods: We compared the requirements of the IQWIG Methodology paper 4.2 and the G-BA rules of procedure for the early benefit assessment for medical drugs ( §35a SGB V) with the new potential analysis for examination and treatment methods. This analysis was made for different criteria's like study and endpoint design, certainty of results of the studies and others. We used our business case as template to extract the key-learning's and identify the pitfalls in the new process. Results: The new legislation will have a strong impact on the study design and evidence to show the potential of new examination and treatment methods as essential treatment alternatives. A lot of evaluation criteria's came from the drug assessments but are hardly applicable to proof the potential of new examination and treatment methods. ConClusions: The legislation uses parts of classic HTA assessment on medical drugs to evaluate the potential of new examination and treatment methods. In most cases this is not possible and will decrease the level of evidence of available clinical data for new examination and treatment methods due to grey zones and loopholes in the legislation.
PHP247 cOrrelaTiOn BeTWeen enD-Of-life sTaTus Of a TreaTmenT anD likeliHOOD Of a PaTienT access scHeme in THe seTTing Of a nice revieW in THe uk
Izmirlieva M. , Ando G.
IHS, London, UK
oBjeCtives: This study aims to assess the existence of a correlation between the applicability of end-of-life treatment criteria and the likelihood of NICE requiring a Patient Access Scheme (PAS) to recommend the treatment for funding. Methods: A review of all patient access schemes in existence as of March 2014 for NICE-recommended drugs was conducted to assess how many of those were for medicines which met the end-of-life treatment criteria and whether the supplementary criteria for end-of-life treatments had any bearing on the final NICE recommendation. Results: In total 42 PAS were identified. Of those, end-of-life treatment criteria were met and had bearing on the final NICE guidance in 7 cases (16.7%). End-of-life treatment criteria were considered but were not met in full in the case of 3 NICE reviews (in one of the three NICE considered that end-of-life criteria were not met in another review, even though the manufacturer had not applied for those criteria to be considered in the present review). End-of-life treatment criteria were also considered for one additional review where they were a focal point of the manufacturer appeal against the NICE guidance. In one additional case, end-of-life criteria were applied for but had no bearing on the final NICE guidance as the cost-effectiveness threshold was met without the application of special considerations. ConClusions: Given the high cost of drugs meeting end-of-life criteria (most of which are for oncology indications), as expected, many of them are subject to a PAS in the UK. However, the opposite correlation does not hold true -i.e., the requirement for a PAS in the UK is not restricted to end-of-life treatments.
HealTH care use & POlicY sTuDies -Patient registries & Post-marketing studies
PHP248 THe cOsTs anD effecTs Of POsT-auTHOrisaTiOn safeTY sTuDies fOr neW acTive suBsTances
Bouvy J. C. 1 , De Bruin M. L. 1 , Hoekman J. 1 , Stolk P. 2 1 Utrecht University, Utrecht, The Netherlands, 2 University of Utrecht, Utrecht, The Netherlands oBjeCtives: At market entry, there usually is uncertainty regarding a new medicine's benefit-risk profile. Therefore, regulatory authorities may request additional pharmacovigilance (PhV) activities. Regulatory Authorities can request a Post-Authorisation Safety Study (PASS) such as a registry, database study, survey, or clinical trial to reduce the uncertainty regarding certain safety risks. We aimed to assess the costs and effects of PASS for centrally approved new active substances (NAS) in Europe in 2007. Methods: We compared two scenarios for all NAS (n= 47):
(1) Full regulation: routine PhV activities (spontaneous adverse drug reaction (ADR) reporting) with additional PASSs for some NAS; (2) Limited regulation: only routine PhV activities. For a follow-up period of six years after marketing we assessed the safety-related labeling changes for NAS and identified the source of these changes (PASS, spontaneous ADR reporting or other). Data on labeling changes was extracted from the European Medicines Agency's website. A survey among pharmaceutical companies was used to estimate the costs of all requested PASSs. Results: For 23 of the 47 NAS, at least one PASS (33 PASS in total) was requested in 2007. After six years, on average 8.1 safety-related labeling changes were identified per NAS. Requested PASS were the source of ~4% of all cases of new safety information identified. The total estimated costs of the 33 requested PASS were between € 50 and € 150 million. ConClusions: For the 2007 cohort of NAS approved in Europe, the total costs of all requested PASS were substantial and yet these PASS contributed to the identification of only 4% of all new safety information identified post-marketing for NAS. However, PASS primarily aim to reduce uncertainty regarding safety risks and the (societal) value of this uncertainty reduction might not fully be captured by assessing health effects alone.
